Mylan (MYL) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Mylan (NASDAQ:MYL) from a sell rating to a hold rating in a report issued on Wednesday morning.

MYL has been the topic of a number of other reports. ValuEngine downgraded Mylan from a hold rating to a sell rating in a report on Wednesday, May 2nd. Zacks Investment Research raised Mylan from a sell rating to a hold rating in a report on Tuesday, January 16th. Susquehanna Bancshares reaffirmed a positive rating and set a $55.00 price target (up from $47.00) on shares of Mylan in a report on Thursday, January 25th. Morgan Stanley set a $50.00 price target on Mylan and gave the company a buy rating in a report on Monday, April 9th. Finally, Cantor Fitzgerald set a $41.00 price target on Mylan and gave the company a hold rating in a report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. Mylan currently has a consensus rating of Buy and an average target price of $47.02.

Shares of Mylan opened at $39.66 on Wednesday, Marketbeat.com reports. The firm has a market cap of $20.44 billion, a PE ratio of 8.70, a price-to-earnings-growth ratio of 1.29 and a beta of 1.35. The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.65 and a current ratio of 1.06. Mylan has a 1 year low of $29.39 and a 1 year high of $47.82.



Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, May 9th. The company reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.99 by ($0.03). The business had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.74 billion. Mylan had a net margin of 6.04% and a return on equity of 18.56%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.93 earnings per share. research analysts predict that Mylan will post 5.36 earnings per share for the current fiscal year.

In other Mylan news, insider Paul Campbell sold 7,030 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total value of $309,390.30. Following the completion of the sale, the insider now owns 17,054 shares in the company, valued at $750,546.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Rajiv Malik sold 50,000 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.91, for a total value of $2,045,500.00. Following the completion of the sale, the president now owns 503,751 shares of the company’s stock, valued at approximately $20,608,453.41. The disclosure for this sale can be found here. In the last three months, insiders sold 269,287 shares of company stock worth $11,034,960. 0.69% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Analyst IMS Investment Management Services Ltd. purchased a new stake in Mylan in the first quarter worth about $117,000. Rational Advisors LLC purchased a new stake in Mylan in the fourth quarter worth about $190,000. Advisor Partners LLC purchased a new stake in Mylan in the fourth quarter worth about $214,000. First Personal Financial Services increased its position in Mylan by 77.1% in the fourth quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock worth $205,000 after buying an additional 2,106 shares in the last quarter. Finally, M Holdings Securities Inc. purchased a new stake in Mylan in the fourth quarter worth about $383,000. Institutional investors and hedge funds own 83.53% of the company’s stock.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply